1
Gong Leyi, Kertesz Denis John, Smith David Bernard, Talamas Francisco Xavier, Wilhelm Robert Stephen: Ccr-3 receptor antagonists. Hoffmann La Roche, March 24, 1999: EP0903349-A2 (86 worldwide citation)

This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.


2
Gong Leyi, Kertesz Denis John, Smith David Bernard, Talamas Francisco Xavier, Wilhelm Robert Stephen: Cyclic amine derivatives. Hoffmann La Roche, April 28, 1999: GB2330580-A (3 worldwide citation)

Cyclic amine derivatives of Formula (I) where the symbols are as defined in the specification, are CCR-3 receptor antagonists. Novel intermediates have the formula:


3
Gong Leyi, Kertesz Denis John, Smith David Bernard, Wilhelm Robert Stephen: 1-substituted 4-aroyl-piperidines. Hoffmann La Roche, May 19, 2000: FR2785902-A1 (2 worldwide citation)

Piperidine derivatives of Formula (I) wherein the symbols are as defined in the specification, and salts thereof are novel compounds that are CCR-3 receptor antagonists which may be useful for treating, e.g., asthma.


4
Dillon Michael Patrick, Jahangir Alam, Lui Alfred Sui Ting, Wilhelm Robert Stephen: Diaminopyrimidines as p2x3 and p3x2/3 modulators. F Hoffmann La Roche, Dillon Michael Patrick, Jahangir Alam, Lui Alfred Sui Ting, Wilhelm Robert Stephen, HEIROTH Ulrike, March 8, 2007: WO/2007/025900 (2 worldwide citation)

Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein A, D, E, G, J, X, Y, Z R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compo ...


5
Gong Leyi, Kertesz Denis John, Smith David Bernard, Wilhelm Robert Stephen: 1-substituted 4-aroyl-piperidines. Hoffmann La Roche, May 24, 2000: GB2343891-A (1 worldwide citation)

Piperidine derivatives of Formula (I) wherein the symbols are as defined in the specification, and salts thereof are novel compounds that are CCR-3 receptor antagonists which may be useful for treating, e.g., asthma.


6
Wilhelm Robert Stephen, Loe Bradley Earl, Devens Bruce Henry, Alvarez Robert, Martin Michael Grant: Benzo and pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity.. Syntex, August 31, 1994: EP0612321-A1 (1 worldwide citation)

Benzo or pyridopyridazinones and pyridazinthiones of formula (I) wherein: X and Y are nitrogen or carbon, provided that at least one is carbon, and Z is oxygen or sulfur; R is hydrogen, lower alkyl, aryl, heteroaryl, or heterocycle lower alkylene; R, R, R, R and R are independently selected from hyd ...


7
ALAM Muzaffar, BHAGIRATH Niala, DU BOIS Daisy Joe, HAWLEY Ronald Charles, KENNEDY SMITH Joshua, WILHELM Robert Stephen: [fr] INHIBITEURS 7-AZAINDOLE DU CRAC, [en] 7-AZAINDOLE INHIBITORS OF CRAC. ALAM Muzaffar, BHAGIRATH Niala, DU BOIS Daisy Joe, HAWLEY Ronald Charles, KENNEDY SMITH Joshua, WILHELM Robert Stephen, F HOFFMANN LA ROCHE, SAUER Frank, June 27, 2013: WO/2013/092467 (1 worldwide citation)

[en] Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associ ...


8
Wilhelm Robert Stephen, Chin Ronnie Lipp, Devens Bruce Henry, Alvarez Robert: Pyrido not 2,3-d pyrimidine derivatives as phosphodiesterase inhibitors. Roche Palo Alto, April 4, 2007: EP1770093-A1

The present invention relates to optionally substituted pyrido-[2,3-d]-pyrimidine-2,4(1H,3H)-diones or optionally substituted pyrido-[2,3-d]-pyrimidine-2(1H,3H)-ones, particularly to 1-(optionally substituted) phenyl-3-(optionally substituted heteroarylalkyl or arylalkyl)-pyrido-[2,3-d]pyrimidine-2, ...


9
Wilhelm Robert Stephen, Fatheree Paul Ross, Chin Ronnie Lipp: Quinoleines en tant quinhibiteurs de la phosphodiesterase de type iv, Quinolines as type iv phosphodiesterase inhibitors. Syntex, Syntex, DENNISON ASSOCIATES, October 13, 1994: CA2159603

Optionally 6,8-substituted quinolines of formula (I) wherein: R1 is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydrozy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; o ...


10